Authors
Takashi Ito, Tsukasa Ikeura, Ayaka Orino, Koh Nakamaru, Masataka Masuda, Shinji Nakayama, Daisuke Hashimoto, Masashi Kanai, Sohei Satoi, Makoto Naganuma
Published in
Pancreas. Sep 21, 2026. Epub Sep 21, 2026.
Abstract
Self-expandable metallic stents (SEMS) are commonly used to treat biliary obstruction in patients with unresectable pancreatic cancer. Fully covered SEMS (FCSEMS) prevents tumor ingrowth but is prone to migration. Multi-hole SEMS (MHSEMS) has multiple holes in the stent membrane, prevents stent migration. This study compared time to recurrent biliary obstruction (TRBO) between MHSEMS and FCSEMS.
We retrospectively enrolled patients with unresectable pancreatic cancer who underwent initial SEMS placement at our institution between January 2017 and December 2025. We evaluated TRBO, causes of obstruction, and stent-related adverse events (AEs). Risk factors for TRBO were assessed using univariate and multivariate analyses.
A total of 116 patients were included; and MHSEMS and FCSEMS were placed in 58 and 58 patients, each. Median TRBO was longer with MHSEMS than FCSEMS (394 vs. 238 d, P<0.01). The MHSEMS group had significantly fewer RBO, including migration, than the FCSEMS group (P=0.01). Multivariate analysis identified MHSEMS use and chemotherapy after SEMS placement as being independently associated with reduced RBO. The rates of AEs, including post-endoscopic retrograde cholangiopancreatography-related pancreatitis, cholecystitis, and non-occlusive cholangitis, were similar between the groups.
MHSEMS may be more effective than FCSEMS in patients with unresectable pancreatic cancer, offering reduced migration risk and better TRBO.
PMID:
42765492
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0